Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Aust N Z J Obstet Gynaecol ; 62(1): 168-171, 2022 02.
Artigo em Inglês | MEDLINE | ID: mdl-34843629

RESUMO

Previous work demonstrated that implementing a quality improvement (QI) program improves the uptake of guideline-recommended antenatal magnesium sulphate, a critical intervention known to reduce cerebral palsy risk. Here we estimate potential cost savings attributable to the improved uptake. By expanding coverage from 63 to 83% of eligible women, we estimated that five children potentially would not have received a diagnosis of cerebral palsy, a potential cost saving of $AU4.8 million in lifetime healthcare costs. Our findings strengthen the case for embedding QI approaches in perinatal care to reduce the incidence of cerebral palsy.


Assuntos
Paralisia Cerebral , Fármacos Neuroprotetores , Nascimento Prematuro , Paralisia Cerebral/prevenção & controle , Criança , Análise Custo-Benefício , Feminino , Humanos , Sulfato de Magnésio/uso terapêutico , Gravidez , Nascimento Prematuro/prevenção & controle , Melhoria de Qualidade
2.
Arch Dis Child Fetal Neonatal Ed ; 107(2): 225-227, 2022 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-34233908

RESUMO

Magnesium sulfate given to women before birth at <30 weeks' gestation reduces the risk of cerebral palsy in their children. Our study aimed to assess the impact of a local quality improvement programme, primarily using plan-do-study-act cycles, to increase the use of antenatal magnesium sulfate. After implementing our quality improvement programme, an average of 86% of babies delivered at <30 weeks' gestation were exposed to antenatal magnesium sulfate compared with a historical baseline rate of 63%. Our study strengthens the case for embedding quality improvement programmes in maternal perinatal care to reduce the impact of cerebral palsy on families and society.


Assuntos
Bloqueadores dos Canais de Cálcio/uso terapêutico , Paralisia Cerebral/prevenção & controle , Doenças do Prematuro/prevenção & controle , Sulfato de Magnésio/uso terapêutico , Feminino , Humanos , Recém-Nascido , Recém-Nascido Prematuro , Gravidez , Nascimento Prematuro/prevenção & controle
3.
Am J Med Genet A ; 118A(4): 377-81, 2003 May 01.
Artigo em Inglês | MEDLINE | ID: mdl-12687672

RESUMO

Sedaghatian type spondylometaphyseal dysplasia is a rare osteochondrodysplasia first described in 1980. The original report describes an Iranian infant with mild rhizomelic limb shortening, severe metaphyseal cupping and irregularity and platyspondyly who died shortly after birth. The baby was born to a consanguineous couple who had reportedly had two similarly affected infants, one male and one female. No documented radiology is available on the female infant. Since this publication, 10 further case reports of male infants with this condition have appeared in the literature all of whom have died shortly after birth. We report a fully documented female case of Sedaghatian type spondylometaphyseal dysplasia providing further evidence to support an autosomal recessive mechanism of inheritance.


Assuntos
Osteocondrodisplasias/diagnóstico por imagem , Osteocondrodisplasias/patologia , Evolução Fatal , Feminino , Humanos , Recém-Nascido , Osteocondrodisplasias/genética , Radiografia , Reino Unido
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA